ABUS News and Press, Arbutus Biopharma Corporation From 06/21/23

Treatment was generally well tolerated with continued HBsAg declines in some patients WARMINSTER, Pa., June 21, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveragi...

WARMINSTER, Pa., June 07, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that two abstracts have been a...

WARMINSTER, Pa., May 31, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral ...

2023-05-22 17:43:28 ET Summary BioNTech SE has initiation of a phase 3 study using BNT316 as a monotherapy for PD-1/PD-L1 refractory non-small cell lung cancer patients that is expected to take place in 2023. Updated results from the expansion cohort from phase 1/2 study using BNT...

2023-05-17 15:17:32 ET Summary Preliminary results from phase 2a study, using AB-729 + Nucleoside analogue + PEG-IFN-2a for the treatment of patients with Hepatitis B, are expected in Q2 of 2023. Results from phase 2a study, using AB-729 + Nucleoside analogue + VTP-300, for the tr...

WARMINSTER, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral ...

2023-05-04 14:54:04 ET Arbutus Biopharma Corporation (ABUS) Q1 2023 Results Conference Call May 04, 2023 08:45 AM ET Company Participants Lisa Caperelli - VP of IR Bill Collier - President, CEO and Director David Hastings - CFO and CAO Karen Sims - VP of Clin...

2023-05-04 07:45:26 ET Arbutus Biopharma press release ( NASDAQ: ABUS ): Q1 GAAP EPS of -$0.10 beats by $0.04 . Revenue of $6.7M (-46.7% Y/Y) beats by $0.67M . As of March 31, 2023, company had cash, cash equivalents and investments in marketable securitie...

Additional AB-729 off-treatment data highlighted in an oral presentation at the Global Hepatitis Summit 2023 Dosed first subject in Phase 1 clinical trial with oral RNA Destabilizer, AB-161 Filed patent infringement lawsuit against Pfizer and BioNTech seeking compensation for us...

Seven patients with cHBV remain off all treatment and continue to maintain low levels of HBV DNA and HBsAg for at least one and half years post- AB-729 treatment AB-161 provides robust anti-HBV activity including suppression of HBV RNA and HBsAg production in preclinical models ...